Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Respiratory

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1544037

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1544037

Alpha-1 Antitrypsin Drugs

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Alpha-1 Antitrypsin Drugs Market to Reach US$4.5 Billion by 2030

The global market for Alpha-1 Antitrypsin Drugs estimated at US$2.3 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2023-2030. Prolastin C Drug, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Glassia Drug segment is estimated at 10.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$651.1 Million While China is Forecast to Grow at 9.0% CAGR

The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$651.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$679.8 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Alpha-1 Antitrypsin Drugs Market - Key Trends and Drivers Summarized

What Is Alpha-1 Antitrypsin Deficiency and Why Are Drugs Needed?

Alpha-1 Antitrypsin (AAT) deficiency is a genetic disorder that can lead to severe respiratory and liver diseases. This condition results from a lack of alpha-1 antitrypsin, a protein produced by the liver that protects the lungs from inflammation caused by infection or irritants like tobacco smoke. Individuals with AAT deficiency are at a higher risk of developing chronic obstructive pulmonary disease (COPD), emphysema, and liver diseases such as cirrhosis and liver cancer. The need for effective drugs is critical, as untreated AAT deficiency can severely impact a patient's quality of life and reduce life expectancy. Current treatments aim to supplement the deficient protein, slow disease progression, and manage symptoms to improve overall health outcomes.

How Are Technological Advancements Influencing Alpha-1 Antitrypsin Drug Development?

Technological advancements have significantly influenced the development of Alpha-1 Antitrypsin drugs, enhancing their efficacy and delivery. Innovations in drug delivery systems, such as inhalable therapies and advanced infusion methods, have improved the convenience and effectiveness of treatment, making it easier for patients to adhere to their medication regimens. Additionally, breakthroughs in genetic and molecular research have paved the way for novel therapies, including gene therapy and recombinant DNA technology, which offer the potential for more targeted and long-lasting treatments. These advancements not only improve patient outcomes but also reduce the frequency of administration and associated healthcare costs, making treatment more accessible and manageable for patients.

What Trends Are Driving the Demand for Alpha-1 Antitrypsin Drugs?

Several trends are driving the increasing demand for Alpha-1 Antitrypsin drugs. Rising awareness and improved diagnostic techniques have led to earlier and more accurate detection of AAT deficiency, resulting in timely treatment initiation. The expanding applications of AAT drugs in treating a broader range of pulmonary and hepatic diseases have also contributed to their growing demand. Moreover, regulatory approvals and support for innovative therapies have accelerated the availability of new treatments in the market. The increasing investment in research and development by pharmaceutical companies highlights the ongoing commitment to improving and expanding treatment options. Furthermore, the growing number of patient advocacy and support groups plays a crucial role in educating the public and healthcare providers about AAT deficiency, driving further demand for effective treatments.

What Factors Are Propelling the Growth of the Alpha-1 Antitrypsin Drugs Market?

The growth in the Alpha-1 Antitrypsin drugs market is driven by several factors, primarily technological advancements, expanding therapeutic applications, and evolving healthcare landscapes. Technological innovations in drug development and delivery systems have significantly enhanced the efficacy and convenience of AAT therapies, making them more attractive to patients and healthcare providers. Expanding therapeutic applications in pulmonary and hepatic diseases have broadened the market, creating new opportunities for drug manufacturers. Additionally, evolving healthcare landscapes, including increased healthcare expenditure and better diagnostic capabilities in emerging markets, have facilitated wider adoption of AAT therapies. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of new and innovative treatments. Furthermore, regulatory support and the rise of personalized medicine are driving the adoption of customized AAT therapies tailored to individual patient needs, ensuring a robust growth trajectory for the market in the coming years.

Select Competitors (Total 43 Featured) -

  • Abeona Therapeutics
  • Alnylam Pharmaceuticals
  • Applied Genetic Technologies Corp
  • Arrowhead Research Corporation
  • Baxalta
  • Baxter
  • CSL Behring
  • Grifols
  • Kamada
  • Shire
  • Takeda Pharmaceutical Company Limited
Show more
Product Code: MCP10246

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Alpha-1 Antitrypsin Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Alpha-1 Antitrypsin Deficiency Propels Demand for Treatment
    • Rising Awareness and Diagnosis Rates Expand Addressable Market Opportunity
    • Innovations in Genetic Therapies Generate Demand for Advanced Alpha-1 Antitrypsin Treatments
    • Growth in Biopharmaceutical Sector Accelerates Development of Alpha-1 Antitrypsin Drugs
    • Expanding Applications in Pulmonary and Hepatic Diseases Drive Market Growth
    • Advances in Biomarker Identification Generate New Opportunities for Targeted Therapies
    • Global Trends towards Personalized Medicine Drive Adoption of Customized Treatments
    • Increasing Focus on Rare Disease Treatment Expands Addressable Market Opportunity for Alpha-1 Antitrypsin Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Alpha-1 Antitrypsin Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Prolastin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Prolastin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Prolastin C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Glassia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Glassia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Glassia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Aralast NP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Aralast NP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Aralast NP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Zemaira / Respreeza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Zemaira / Respreeza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Zemaira / Respreeza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • JAPAN
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • CHINA
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • EUROPE
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • FRANCE
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • GERMANY
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!